Zidesamtinib demonstrates 93% response rate in ROS1-positive lung cancer
New results from the global phase 1/2 ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who ...
14 Sep 01:50 · Medical Xpress